HOME >> MEDICINE >> NEWS
Fox Chase study: Radiation then tamoxifen after lumpectomy for early-stage breast cancer pts

DENVER--Fox Chase Cancer Center researchers say the sequence of tamoxifen and radiation following lumpectomy for early-stage breast cancer patients does not affect disease control, survival or complication rates, but administering tamoxifen concurrently with radiation has negative cosmetic results. These findings of this study, the largest known series of data examining the sequencing of tamoxifen and radiation, were presented today at the 47th Annual Meeting of the American Society for Therapeutic Radiology and Oncology in Denver, Colo.

"Prior to this study, the sequencing of radiation and tamoxifen following lumpectomy had not been well-established," explained Penny Anderson, M.D., a radiation oncologist at Fox Chase Cancer Center in Philadelphia and lead author of the study. "Some studies have suggested a potential negative effect of tamoxifen on radiosensitivity when the drug was administered during radiation treatments, while other studies have not demonstrated an adverse effect."

Anderson's study included 1,088 women with stage I/II breast cancer who underwent breast-conserving surgery and radiation therapy and received adjuvant tamoxifen (with or without chemotherapy) between 1982 and 2004. Of these, 699 patients received tamoxifen after completing radiation (sequential) and 389 patients received tamoxifen during radiation therapy (concurrent).

There were no statistically significant differences observed between the sequential group and the concurrent group for disease control and survival. However, there was a statistically higher rate of excellent/good cosmesis in the sequential group compared to the concurrent group (95 percent versus 88 percent).

"Previous studies have shown that quality-of-life issues such as the appearance of the affected breast after treatment is important to women," said Anderson. "We continue to recommend sequential sequencing of tamoxifen and radiation, but concurrent administration has acceptable outcomes
'"/>

Contact: Karen C. Mallet
karen.mallet@fccc.edu
215-728-2700
Fox Chase Cancer Center
16-Oct-2005


Page: 1 2

Related medicine news :

1. Fox Chase study examines which women could benefit from adjuvant therapy with aromatase inhibitor
2. Fox Chase study shows TURP patients with intermediate PSA should be considered high-risk
3. NCI/Fox Chase Cancer Center Science Writers Seminar
4. HealthGrades study: Bariatric surgery patients have fewer complications at high-volume hospitals
5. Case study: cross-cultural bioethics training program helps fight African brain drain
6. New study: Pycnogenol reduces heart failure
7. New study: Pine bark significantly reduces endometriosis
8. FSU study: Can prunes reverse bone loss after menopause?
9. New study: Preterm birth causes one-third of all infant deaths
10. FSU study: Abortion notification, consent laws reduce risky teen sex
11. National study: Patients poorly prepared for end-of-life decisions

Post Your Comments:
(Date:6/18/2013)... (PRWEB) June 19, 2013 Looking for a ... monotony of everyday life? , IWALKAWAKE is a guide ... Written by Adam Botha, it focuses on harnessing the powerful ... The book lays out a nine-step guide to finding one’s ... that a person must go through to reach their true ...
(Date:6/18/2013)... Daily Gossip Magazine has always kept its readers entertained ... , The magazine has decided to prepare readers for the ... recipe every week . , According to Daily Gossip ... readers who are looking to get insights into this type ... anabolic food is almost entirely based on healthy, yet tasteful ...
(Date:6/18/2013)... (PRWEB) June 18, 2013 SEATTLE, WA—A ... Farms of Fairview, Oregon, claiming he fell ill with ... berry and pomegranate seed blend. The complaint was ... by Marler Clark, the Seattle-based law firm that has ... , According to the complaint, Brian Brothers consumed “Townsend ...
(Date:6/18/2013)... Warner, NH (PRWEB) June 18, 2013 ... rugged, submersible, battery powered, stand-alone device which can be ... The new stainless steel enclosure of the Temp1000IS comes ... device interfaces with the IFC400 (sold separately) ... docking station for full communications. No more removal of ...
(Date:6/18/2013)... Senior drug regulatory officials from mainland China and Taiwan ... first time in the U.S.—the need for more collaboration between ... in a timely manner. Representatives from the Taiwan and mainland ... and processes in drug review during the Convergence in ... DIA 2013 49th Annual Meeting . , While ...
Breaking Medicine News(10 mins):Health News:Anabolic Cooking Book Review Exposes Dave Ruel’s Top 10 ‘Anabolicious’ Recipes for BodyBuilders 2Health News:Marler Clark, Washington Resident Sue Townsend Farms Over Hepatitis A 2Health News:Marler Clark, Washington Resident Sue Townsend Farms Over Hepatitis A 3Health News:MadgeTech, Inc. Introduces the New Temp1000IS Intrinsically Safe High Temperature Data Logger 2Health News:Renowned Regulatory Representatives From Mainland China and Taiwan to Discuss Need for Collaboration at DIA Meeting 2
(Date:6/18/2013)... , Safinamide significantly improves ... as add-on to levodopa Safinamide is ... in fluctuating PD patients as add-on to levodopa ... ("Newron"), a research and development company focused on ... Zambon S.p.A., a pharmaceutical company strongly committed to ...
(Date:6/18/2013)... -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... VPII Escrow Corp., a newly formed wholly owned Canadian ... approximately $3.2 billion aggregate principal amount of senior unsecured ... 2021 and in 2023, with final tranching determined at ... net proceeds from the offering, together with proceeds from ...
(Date:6/18/2013)... 2013  Intercept Pharmaceuticals, Inc.  (NASDAQ: ICPT ... development and commercialization of novel bile acid therapeutics to ... an underwritten public offering of 1,730,000 shares of its ... per share.  In addition, Intercept has granted the underwriters ... 259,500 shares of common stock. All of ...
Breaking Medicine Technology:Safinamide Phase III Study Results Presented at 2013 MDS Meeting 2Safinamide Phase III Study Results Presented at 2013 MDS Meeting 3Safinamide Phase III Study Results Presented at 2013 MDS Meeting 4Safinamide Phase III Study Results Presented at 2013 MDS Meeting 5Safinamide Phase III Study Results Presented at 2013 MDS Meeting 6Valeant Pharmaceuticals Announces Launch Of Private Offering Of Senior Notes 2Valeant Pharmaceuticals Announces Launch Of Private Offering Of Senior Notes 3Intercept Pharmaceuticals Announces Pricing of Public Offering of Common Stock 2
Cached News: